Value
7.3/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 4.7 |
| Analyst target | 9.0 |
- ▸Attractively valued
SNDX · Why this verdict
Why Syndax Pharmaceuticals (SNDX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Syndax Pharmaceuticals is a cash-burning biotechnology company with analyst consensus implying 111% upside, heavy concentration in two commercial-stage drugs (Revuforj and Niktimvo), and 19% short interest — a high-asymmetry speculative position where the bull and bear cases are both extreme.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Syndax's commercial revenue is concentrated entirely in two products — Revuforj and Niktimvo — meaning the success or failure of these two drugs determines the company's path to commercial viability, with no revenue diversification to buffer setbacks. Bear case | Combined net product revenue from Revuforj and Niktimvo grows by more than 50% year-over-year over the next 12 months, demonstrating commercial uptake momentum. | →Stable |
| CounterEarly-stage specialty oncology and GVHD drugs often build slowly as physicians gain experience; concentrating on 2 products is standard for companies at this stage and does not necessarily reflect unusual risk. | ||
Analyst consensus implies approximately 111% upside from the current price of $18.48 to a target of $33.93, reflecting significant expected value if the two commercial products achieve their market penetration targets. Sentiment breakdown | Price rises above $28, more than 50% above the current $18.48, over the next 12 months as commercial revenue data improves investor confidence. | →Stable |
| CounterBiotech analyst targets for small commercial-stage companies carry wide uncertainty ranges and are frequently revised sharply downward when trials disappoint or commercial adoption lags projections. | ||
Free cash flow is -86% of revenue, indicating the company burns cash at a rate that materially exceeds revenue generation — a pattern that creates ongoing dilution risk as the company raises capital to fund operations. Quality breakdown | Cash burn rate decreases to below 50% of revenue over the next 12 months as commercial product sales scale and expenses stabilize. | →Stable |
| CounterA weak Piotroski F-Score of 3/9 and below-floor quality rating already reflect the cash burn, and the strong current ratio suggests adequate liquidity for the near term without emergency capital raises. | ||
Short interest of 19% and an elevated put/call ratio of 1.85 indicate substantial market skepticism about the commercial trajectory of Revuforj and Niktimvo, with sophisticated investors placing large bets on downside scenarios. Key risks | Short interest falls below 12% over 12 months as commercial revenue growth data reduces the market's uncertainty about product uptake. | →Stable |
| CounterOn-balance volume is rising and the 200-day moving average slope is still trending upward at +5.6%, suggesting that buyers are absorbing the short pressure rather than capitulating. | ||
Syndax's commercial revenue is concentrated entirely in two products — Revuforj and Niktimvo — meaning the success or failure of these two drugs determines the company's path to commercial viability, with no revenue diversification to buffer setbacks.
→StableBear case
- Expectation
- Combined net product revenue from Revuforj and Niktimvo grows by more than 50% year-over-year over the next 12 months, demonstrating commercial uptake momentum.
CounterEarly-stage specialty oncology and GVHD drugs often build slowly as physicians gain experience; concentrating on 2 products is standard for companies at this stage and does not necessarily reflect unusual risk.
Analyst consensus implies approximately 111% upside from the current price of $18.48 to a target of $33.93, reflecting significant expected value if the two commercial products achieve their market penetration targets.
→StableSentiment breakdown
- Expectation
- Price rises above $28, more than 50% above the current $18.48, over the next 12 months as commercial revenue data improves investor confidence.
CounterBiotech analyst targets for small commercial-stage companies carry wide uncertainty ranges and are frequently revised sharply downward when trials disappoint or commercial adoption lags projections.
Free cash flow is -86% of revenue, indicating the company burns cash at a rate that materially exceeds revenue generation — a pattern that creates ongoing dilution risk as the company raises capital to fund operations.
→StableQuality breakdown
- Expectation
- Cash burn rate decreases to below 50% of revenue over the next 12 months as commercial product sales scale and expenses stabilize.
CounterA weak Piotroski F-Score of 3/9 and below-floor quality rating already reflect the cash burn, and the strong current ratio suggests adequate liquidity for the near term without emergency capital raises.
Short interest of 19% and an elevated put/call ratio of 1.85 indicate substantial market skepticism about the commercial trajectory of Revuforj and Niktimvo, with sophisticated investors placing large bets on downside scenarios.
→StableKey risks
- Expectation
- Short interest falls below 12% over 12 months as commercial revenue growth data reduces the market's uncertainty about product uptake.
CounterOn-balance volume is rising and the 200-day moving average slope is still trending upward at +5.6%, suggesting that buyers are absorbing the short pressure rather than capitulating.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Op margin | 0.0 |
| Current ratio | 7.5 |
| FCF quality | 0.0 |
| Moat | 4.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -86% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 75)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.4 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 91%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $1,336,019 (0.075% of mkt cap)
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.9 |
| quality rank | 0.0 |
| growth rank | 9.5 |
- ▸Industry growth leader
Technical
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.3 |
| support resistance | 0.7 |
| 52w position | 6.0 |
Risk (lower is worse)
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.6 |
| days to cover | 0.0 |
| volatility | 2.6 |
| put call | 8.2 |
| implied vol | 0.9 |
| max pain risk | 7.0 |
| beta | 10.0 |
| debt equity | 0.0 |
- ▸High short interest justified: 19%
- ▸High IV: 74%
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 2.9 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.7>=5.5
- ASYMMETRY:4.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:39d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
4.41
Upside
+66.1%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.8B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 8.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 8.0, Value at 7.3, and Momentum at 6.7; the weakest are Technical at 2.3, Quality at 2.5, and Risk (lower is worse) at 3.8. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 4.41 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Syndax's commercial revenue is concentrated entirely in two products — Revuforj and Niktimvo — meaning the success or failure of these two drugs determines the company's path to commercial viability, with no revenue diversification to buffer setbacks.
Trip ifCombined net revenue from Revuforj and Niktimvo falls below $10 million in any reported quarter, indicating commercial adoption is failing to gain traction.
- P2Analyst consensus implies approximately 111% upside from the current price of $18.48 to a target of $33.93, reflecting significant expected value if the two commercial products achieve their market penetration targets.
Trip ifAnalyst consensus price target falls below $20, less than 10% above the current price of $18.48, indicating the upside case is being abandoned.
- P3Free cash flow is -86% of revenue, indicating the company burns cash at a rate that materially exceeds revenue generation — a pattern that creates ongoing dilution risk as the company raises capital to fund operations.
Trip ifQuarterly operating cash outflow exceeds $80 million for 2 consecutive quarters, indicating the cash burn is accelerating beyond current projections.
- P4Short interest of 19% and an elevated put/call ratio of 1.85 indicate substantial market skepticism about the commercial trajectory of Revuforj and Niktimvo, with sophisticated investors placing large bets on downside scenarios.
Trip ifShort interest rises above 25% or the put/call ratio exceeds 3.0, indicating market conviction about downside is intensifying significantly.